HSBC Holdings
JANX icon

HSBC Holdings’s Janux Therapeutics JANX Stock Holding History

HSBC Holdings’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$686K Sell
44,101
-7,162
-14% -$104K ﹤0.01% 2133
2026
Q1 		$711K Buy
+51,263
New +$703K ﹤0.01% 2046

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

HSBC Holdings's JANX Position: Q2 2026 in Review

HSBC Holdings reduced its Janux Therapeutics (JANX) stake by 14% in Q2 2026, selling an estimated $104K and leaving 44,101 shares worth $686K. The position accounts for ﹤0.01% of the portfolio, ranked #2133.

HSBC Holdings first reported a position in JANX in Q1 2026 and has held it in 2 quarters since. The position peaked at $711K in Q1 2026. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • HSBC Holdings held 44,101 shares of Janux Therapeutics worth $686K as of Q2 2026.
  • HSBC Holdings sold 7,162 Janux Therapeutics shares in Q2 2026, an estimated $104K.
  • Janux Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2133 holding.
  • HSBC Holdings first reported a position in Janux Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • HSBC Holdings's Janux Therapeutics position peaked at $711K in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.